COLCHICINE-INDUCED HEPATOTOXICITY

Altuğ Şenol Assoc. Prof. MD¹, Mehmet İşler Prof. MD¹, Muhammed Cem Koçkar Assoc. Prof. MD¹, Erkan Çüre MD², Yıldızan Songür Prof. MD¹

¹Süleyman Demirel University, Medical Faculty, Department of Gastroenterology, Isparta, TURKEY
²Safranbolu State Hospital, Department of Internal Medicine, Safranbolu, TURKEY

ABSTRACT

Colchicine is an agent that is used for the treatment of inflammatory disease such as Familial Mediterranean Fever (FMF) and acute gouty arthritis. Therapeutic oral doses of colchicine therapy are associated with numerous adverse effects. Gastrointestinal symptoms due to increased peristaltic activity are common. However, no cases of colchicine induced hepatotoxicity have been reported in the literature with the therapeutic oral doses. We report a case of colchicine induced hepatotoxicity in a 38 year old patient with FMF.


ÖZET

KOLSİSİN KULLANIMINA BAĞLI GELİŞEN HEPATOTOKSİSİTE


AAA’lı 38 yaşındaki bir hastada kolsisine bağlı gelişen hepatotoksisite vakası sunulacaktır.

INTRODUCTION

Drugs are important causes of the liver injury. The severity of injury may vary from minor non-specific changes in hepatic structure and function to fulminant hepatic failure and chronic hepatitis. Colchicine induced hepatotoxicity is a rare condition in clinical practice.

Colchicine is derived from the corms of colchicum autumnale and is used primarily to treat familial Mediterranean fever (FMF) attacks and FMF-associated amyloidosis, as well as for the treatment of acute gouty arthritis and prophylaxis of recurrent attacks. In here, we report a case of colchicine induced hepatotoxicity in a 38 year old patient with FMF.

CASE REPORT

A 38 year old man was admitted to emergency department with acute attack of intermittent abdominal pain which has been started when he was 10 years old. His abdominal pain was appearing from right hypochondriac region and was expanding to all abdomens. Fever was usually accompanying to pain and both were lasting two or three days. At the beginning of pain attack was seen in monthly, but in recent it became weekly. On admission he had no constipation, vomiting and nausea. Physical examination was normal except abdominal tenderness. Erythrocyte sedimentation rate (ESR) was 73 mm/h, C reactive protein (CRP) was 55 mg/l (normal: 0–5 mg/l), fibrinogen was 4/L (normal: 2.0–4.0, g/dl), white blood cell count (WBC) was 5.700/ml, hemoglobin was 13.2 g/dl, blood glucose, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT) were normal, alkaline phosphates (ALP) was 215 (normal: 53-28 U/L).

Upper gastrointestinal endoscopy showed antral gastritis. His abdominal pain was disappeared three days later. At day 5, ESR was 51 mm/hour, WBC was 5.900/mL, CRP was 22.7 mg/L, fibrinogen was 2.87/L. Familial Mediterranean fever gene mutation test revealed M6801 (G/C) homozygote mutation. Colchicine 0.5 mg t.i.d has been started. Abdominal pain has not occurred during one month. Routine laboratory control showed AST of 103 U/L and ALT of 193 U/L, one month later. He was taking no drug except colchicine and no alcohol at that time. Liver parenchyma echogenicity and liver size were normal ultrasoundographically. Serum albumin, prothrombin time, ALT and thyroid stimulating hormone levels were in normal ranges. Anti-HAV IgG was positive, anti-HAV IgM, HbsAg, anti-HBc IgM, anti-HCV, HCV-RNA and anti-HIV were negative. Antinuclear antibody, anti-smooth muscle antibody, and anti-liver-kidney microsomal type 1 antibody were also within normal ranges. Thereafter dose of colchicum was decreased to 0.5 mg b.i.d. Fifteen days later, AST was 98 U/L and ALT was 245 U/L. So colchicum was stopped. One month later, AST was 20 U/L and ALT was 29 U/L. However, about two weeks later he had abdominal pain again. So colchicine was started again. One month later AST was 49 U/L and ALT was 151 U/L, so colchicum was stopped again. Twenty days later AST and ALT levels were detected as normal. Afterwards abdominal pain attack was recurred, and so azathioprine was started. Now, he has no abdominal pain and transaminase levels are still normal in one year follow up.

DISCUSSION

The diagnosis of drug-induced hepatotoxicity is based on exclusion of other possible causes of hepatic dysfunction and on close to association between drug administration and the onset of liver disease while liver biopsy may allow a correct diagnosis. In literature, there are few case reports of hepatotoxicity associated with colchicine poisoning, but no case of hepatotoxicity induced by therapeutic doses colchicine has been reported. Atag et al. reported to findings of colchicine poisoning such as gastrointestinal symptoms, hepatotoxicity, cardiotoxicity, bone marrow suppression, hypocalcaemia, hair loss and died.

Crozeni et al. reported that colchicine-induced hepatotoxicity in experimental models depends on the magnitude and composition of the bile salt flux traversing the liver. Colchicine significantly impairs hepatocyte integrity argue for caution in interpreting previous data obtained using microtubule-disrupting agents as a tool to assess vesicular transport in the liver.

Colchicine is effective in a dose of 0.015 mg/kg, toxic in dose greater than 0.1 mg/kg, and lethal in a dose of 0.8 mg/kg. Thus, therapeutic range of colchicine level is narrow. In our patient, serum AST and ALT levels were increased 5 times when oral colchicine was used 1.5 mg/day. So colchicine was discontinued. After 2 weeks of discontinuation of colchicine therapy, liver function tests were decreased to normal levels.

As the abdominal pain was recurred after drug therapy was discontinued, so colchicine was started again. At follow up, liver function tests were increased 4 or 5 times again. We could not examine serum colchicine levels in our patient. Because of the increase in the serum aminotransferase levels with the beginning of colchicine and come to the normal levels when the drug stopped and also with the negative serology.
for acute viral infection, negative autoantibody markers and exclusion of other drugs or potentially hepatotoxic agents, we believed that when the colchicine is used in the therapeutic doses it causes hepatotoxicity. In conclusion, patients treated with colchicine need control of liver function tests.

REFERENCES

8 Niel E, Scherrmann JM. Colchicine today. Joint Bone Spine 2006; 73; 672-678.